Opinion · Supreme Court of the United States
Sandoz Inc. v. Amgen Inc.
Sandoz Inc. v. Amgen Inc., 582 U.S. 1 (Supreme Court of the United States 2017)
- Type
- Opinion
- Court
- Supreme Court of the United States
- Jurisdiction
- Federal
- Date
- 2017-06-12
- Topic
- general
Justice BREYER, concurring. The Court's interpretation of the statutory terms before us is a reasonable interpretation, and I join its opinion. In my view, Congress implicitly delegated to the Food and Drug Administration authority to interpret those same terms. That being so, if that agency, after greater experience administering this statute, determines that a different interpretation would better serve the statute's objectives, it may well have authority to depart from, or to modify, today's interpretation, see National Cable & Telecommunications Assn. v. Brand X Internet Services, 545 U.S. 967, 982-984, 125 S.Ct. 2688, 162 L.Ed.2d 820 (2005), though we need not now decide any such matter.
Citator
UpLaw has not yet analyzed Sandoz Inc. v. Amgen Inc.. The absence of a flag is not a finding that it is good law.
The Court's interpretation of the statutory terms before us is a reasonable interpretation, and I join its opinion. In my view, Congress implicitly delegated to the Food and Drug Administration authority to interpret those same terms. That being so, if that agency, after greater experience administering this statute, determines that a different interpretation would better serve the statute's objectives, it may well have authority to depart from, or to modify, today's interpretation, see National Cable & Telecommunications Assn. v. Brand X Internet Services, 545 U.S. 967, 982-984, 125 S.Ct. 2688, 162 L.Ed.2d 820 (2005), though we need not now decide any such matter.